kabutan

Noile-Immune Biotech Inc.(4893) Summary

4893
TSE Growth
Noile-Immune Biotech Inc.
150
JPY
+1
(+0.67%)
Apr 28, 3:30 pm JST
0.94
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
1.65
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
150 JPY 0.94 USD
Previous Close Apr 27
149 JPY 0.93 USD
High Apr 28, 1:56 pm
151 JPY 0.94 USD
Low Apr 28, 9:13 am
148 JPY 0.92 USD
Volume
68,500
Trading Value
0.01B JPY 0.06M USD
VWAP
150.04 JPY 0.94 USD
Minimum Trading Value
15,000 JPY 94 USD
Market Cap
6.50B JPY 0.04B USD
Number of Trades
65
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
Mid
1-Year Average
273
1-Year High Jul 2, 2025
8,956
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 1,720,000 1,660,800 0.97
Apr 17, 2026 1,837,500 1,602,800 0.87
Apr 10, 2026 1,838,100 1,681,400 0.91
Apr 3, 2026 1,838,100 1,722,000 0.94
Mar 27, 2026 1,838,100 1,784,300 0.97
Company Profile
Noile-Immune Biotech Inc. engages in the development of novel immunotherapies utilizing CAR-T cells for cancer treatment.
Sector
Pharmaceuticals
Noile-Immune Biotech Inc. focuses on developing novel immunotherapies utilizing CAR-T cells for cancer treatment. The company aims to develop effective CAR-T cell therapies for solid tumors using its proprietary PRIME technology. PRIME technology is a platform technology that can be applied to regenerative medicine, with the potential to achieve superior cancer treatment effects by activating immune cells within the patient's body. It promotes the infiltration and activation of immune cells into solid tumor tissues. Noile-Immune Biotech pursues two business models: in-house drug discovery and collaborative pipelines, with multiple pipelines in progress. The company is also conducting clinical trials targeting solid tumors, exploring new possibilities in cancer immunotherapy.